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Objectives. This study sought to define the local regulation of
vascular tissue-type plasminogen activator (t-PA) release.
Background. The vascular endothelium, through the produc-
tion of t-PA and plasminogen activator inhibitor (PAI-1), is an
important regulator of fibrinolysis. Plasma t-PA levels increase in
response to adrenergic stimulation; however, it is unclear whether
this increase is the result of systemic reflex responses or direct
effects on the vascular endothelium.
Methods. Forearm blood flow dose responses were generated to
low doses of agonist infused directly into the brachial artery in 15
normotensive men (mean [6SE] age 28.9 6 2.2 years). Simulta-
neous arterial and venous blood samples were drawn at baseline
and in response to the intraarterial administration of isoproter-
enol (400 ng/min), methacholine (8 mg/min) and sodium nitro-
prusside (SNP) (8 mg/min). PAI-1 and t-PA antigen levels were
measured by enzyme-linked immunosorbent assay, and the net
release across the forearm was calculated.
Results. Forearm plasma flow increased significantly from
baseline (1.4 6 0.2 ml/100 ml per min) after administration of
isoproterenol, methacholine and SNP (9.7 6 1.9, 8.7 6 1.9 and
6.7 6 1.1 ml/100 ml per min, respectively) (p < 0.001 by analysis
of variance). Baseline net t-PA release (0.7 6 0.3 ng/100 ml per
min) increased significantly after administration of isoproterenol
(26.2 6 11.6 ng/100 ml per min, p 5 0.005) and methacholine
(15.3 6 5.5 ng/100 ml per min, p 5 0.001) but not after
administration of SNP (1.8 6 2.2 ng/100 ml per min, p 5 0.84).
There was no net release of PAI-1 across the vascular bed.
Conclusions. Marked, rapid local t-PA release occurred in
response to isoproterenol, a beta-adrenoceptor agonist, and
methacholine, an endothelium-dependent nitric oxide agonist, in
the human forearm. This effect was selective and independent of
the effects of shear stress due to increased flow because SNP
induced similar increases in forearm blood flow without affecting
t-PA release. Vascular t-PA release may be a potentially valuable
tool for evaluating endothelial function in diseases associated with
increased risk of thrombosis.
(J Am Coll Cardiol 1998;32:117–22)
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The vascular endothelium, through the production of prosta-
cyclin, nitric oxide (NO), a tissue-type plasminogen activator
(t-PA) and plasminogen activator inhibitor (PAI-1), is a key
regulator of thrombosis and fibrinolysis. Reduced fibrinolytic
activity is associated with an increased risk of myocardial
infarction, stroke and cardiovascular mortality (1–5). Common
clinical conditions, including heart failure and hypertension,
which are associated with adrenergic activation and abnormal
endothelium-mediated responses (6–9), are also associated
with altered fibrinolysis and increased risk of cardiovascular
events. Therefore, although an understanding of the homeo-
static regulation of fibrinolysis under basal conditions is of
interest, the regulation of fibrinolysis under conditions associ-
ated with adrenergic or endothelial activation may be of
greater clinical importance. The role of adrenergic and other
stimuli in the regulation of local t-PA production in humans is
poorly characterized; however, several animal studies suggest
that both adrenergic stimulation and endothelial NO produc-
tion increase the release of t-PA (10–12). The majority of
studies in humans addressing the role of adrenergic activation
in the regulation of t-PA release have measured circulating
t-PA concentrations after systemic infusion of an agonist and
have suggested that adrenergic activation resulted in increased
fibrinolysis and t-PA concentrations (13–16). Unfortunately,
such studies are limited in that circulating t-PA concentrations
represent the sum of t-PA release and clearance, both of which
may be affected, not only by drugs, but also by changes in blood
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flow (13,14,17). Thus, the mechanism underlying the increased
circulating t-PA concentrations noted after exercise, mental
stress and administration of adrenergic agonists has remained
controversial. Recently, complex modeling has been per-
formed in an attempt to quantify the contribution of local
mechanisms to the increase in fibrinolytic activity after exercise
and systemic administration of adrenergic agonists (13,14). A
more attractive and direct approach to the study of the local
mechanisms regulating fibrinolysis involves the direct infusion
of agents into a specific vascular bed, at doses that have
minimal systemic effects. Blood is then sampled from the
inflow and outflow of that vascular bed, thus permitting
measurement of local t-PA release, free of the confounding
effects of systemic reflex responses (18,19). The purpose of the
present study was to measure the local production of t-PA in
response to direct intrabrachial artery administration of iso-
proterenol, a beta-adrenergic agonist. To control for shear
stress–induced increases in t-PA release, the responses to
infusion of methacholine and sodium nitroprusside (SNP) at
similar levels of increased blood flow were determined.
Methods
Subjects. Fifteen healthy, normotensive, nonsmoking male
volunteers (mean [6SE] age 28.9 6 2.2 years) were studied.
Nine subjects were black, and six were white. No subject had
clinically significant abnormalities on history, physical exami-
nation or routine laboratory tests, including complete blood
count, prothrombin and partial thromboplastin times; renal
and liver function tests; and an electrocardiogram (ECG).
Subjects did not take any medications for at least 2 weeks
before each study day and abstained from caffeine and alcohol
for 5 days before each study day. All subjects provided written
informed consent, and the study protocol was approved by the
Vanderbilt Committee for the Protection of Human Subjects.
These subjects were participating in studies examining ethnic
differences in vascular flow responses, and those data have
been published elsewhere (20,21).
Experimental protocol. All experiments were performed in
the morning, in the same temperature-controlled room, with
the subjects resting supine in bed. An intravenous cannula was
placed in an antecubital vein of both arms. After subdermal
administration of 1% lidocaine, an 18-gauge polyurethane
catheter (Cook) was inserted into the brachial artery of the
nondominant arm, allowing direct intraarterial administration
of drugs. Arterial catheter patency before the infusion of
isoproterenol was maintained with an infusion of normal saline
at a rate of 30 ml/h and before the infusion of methacholine or
SNP, with a 40-ml/h infusion of 5% dextrose in water. By
altering the concentration of the drug infusion, the total flow
rate through the canula was maintained constant at 30 ml/h
during intraarterial administration of isoproterenol and at 40
ml/h during the administration of methacholine and SNP.
Arterial blood pressure was measured by means of a pressure
transducer (Hewlett-Packard), and heart rate was recorded
from a continuous ECG monitor. A trace dose of [3H]norepi-
nephrine was infused intravenously into the arm contralateral
to the arterial line for the determination of norepinephrine
kinetics, and those data have been reported elsewhere (20).
After the arterial line and intravenous catheters had been
placed, subjects rested quietly for 60 min. Baseline measure-
ments were determined, and isoproterenol 10 to 400 ng/min, in
incremental doses, was infused intraarterially using a Harvard
infusion pump (Harvard Apparatus). Each dose of isoproter-
enol was infused for 7 min, with blood flow recordings per-
formed during the last 2 min. After completion of the isopro-
terenol dose response, 5% dextrose in water was infused at a
rate of 40 ml/h for a washout period of 30 to 40 min until
forearm blood flow had returned to baseline. Methacholine
(0.25 to 8 mg/min) and SNP (0.25 to 8 mg/min), in random
order, were infused intraarterially in incremental doses. Each
dose was infused for 5 min, with measurements of forearm
blood flow made during the last 2 min of each infusion. A
30-min washout period between the infusion of the two drugs
allowed blood flow to return to baseline before infusion of the
second drug.
Blood was drawn simultaneously from the brachial artery
and antecubital vein from the arm into which drugs were
infused at baseline and after the infusion of the highest doses
of isoproterenol (400 ng/min), methacholine (8 mg/min) and
SNP (8 mg/min). In one subject, for technical reasons, the SNP
response was determined using the second highest dose (4
mg/min). Samples were drawn into cooled tubes with ethyl-
eneglycoltetraacetic acid (EGTA) and reduced glutathione
(Amersham Corporation), placed on ice and centrifuged at
4°C, separated and immediately frozen.
Forearm blood flow was measured, using mercury in Silastic
strain gauge plethysmography (22), in the arm into which
vasodilators were infused intraarterially, as previously de-
scribed (20,21). The wrist was supported in a sling to raise the
level of the forearm to above that of the atrium. The hand was
excluded from the measurement of blood flow by inflation of a
pediatric sphygmomanometer cuff to 200 mm Hg around the
wrist before and during measurement of forearm blood flow.
The volume of the forearm, excluding the hand and wrist, was
measured by water displacement.
The arterial concentrations of t-PA and PAI-1 antigen,
determined as described below, were subtracted from their
respective venous concentrations at each sampling point to
determine the arteriovenous concentration gradient (V–A). A
positive arteriovenous gradient indicates net release, whereas a
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ECG 5 electrocardiogram, electrocardiographic
NO 5 nitric oxide
PAI-1 5 plasminogen activator inhibitor
SNP 5 sodium nitroprusside
t-PA 5 tissue-type plasminogen activator
V-A 5 arteriovenous concentration gradient
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negative one would reflect net uptake in the forearm. The net
release was calculated as the arteriovenous concentration gra-
dient multiplied by the forearm plasma flow. Forearm plasma
flow was derived from the hematocrit and the forearm blood
flow.
Analytic methods. Antigen levels of t-PA and PAI-1 were
measured using commercially available enzyme-linked immu-
nosorbent assays (Biopool AB, Umea, Sweden), as previously
described (23).
Statistical analysis. Results are expressed as mean value 6
SE, and were analyzed by repeated measures analysis of
variance (ANOVA) and with post hoc testing performed using
the t test for paired samples or, for data that were not normally
distributed, the Wilcoxon matched pairs signed-rank test with
the Bonferroni correction for multiple comparisons (SPSS for
Windows Release 6). Because the primary, predefined out-
come of interest in the study was net t-PA release across the
forearm, this was the outcome subjected to post hoc testing. A
two-tailed p value ,0.05 was the criterion for statistical
significance.
Results
Subjects were healthy and did not have risk factors for
endothelial dysfunction, except for two subjects whose serum
cholesterol concentrations were 256 and 265 mg/dl. The de-
mographic data of the subjects studied are shown in Table 1.
Forearm plasma flow increased significantly from baseline
(1.4 6 0.2 ml/100 ml per min) after the administration of
agonists, resulting in responses to isoproterenol (400 ng/min),
methacholine (8 mg/min) and SNP (8 mg/min) of 9.7 6 1.9,
8.7 6 1.9 and 6.7 6 1.1 ml/100 ml per min, respectively (p ,
0.001 by ANOVA), representing a 7.3-, 6.5- and 5.1-fold
increase in forearm plasma flow in response to isoproterenol,
methacholine and SNP, respectively (not significantly different:
p 5 0.14 by ANOVA). Venous concentrations of t-PA antigen
increased from a baseline value of 3.0 6 0.5 ng/ml to 4.9 6 0.5
ng/ml and 4.4 6 0.8 ng/ml after infusion of isoproterenol and
methacholine, respectively, but not after SNP (3.2 6 0.6 ng/ml)
(Table 2). Arterial t-PA antigen concentrations during the
infusion of isoproterenol, methacholine and SNP were similar.
Thus the arteriovenous concentration gradient of t-PA antigen
and the net release of t-PA antigen increased significantly after
the infusion of isoproterenol and methacholine but not after
SNP. The net t-PA antigen release increased from 0.7 6 0.3
ng/100 ml per min at baseline to 26.2 6 11.6 ng/100 ml per min
(p 5 0.005) and 15.3 6 5.5 ng/100 ml per min (p 5 0.001) after
infusion of isoproterenol and methacholine, respectively, but
was not significantly altered by SNP (1.8 6 2.2 ng/100 ml per
min, p 5 0.84) (Table 2, Fig. 1). This response represents a 38-,
22- and 2-fold increase in net t-PA release in response to
isoproterenol, methacholine and SNP, respectively.
Arterial and venous PAI-1 antigen concentrations at base-
line were similar (13.5 and 13.6 ng/ml), with no significant
Table 1. Demographic Characteristics of 15 Study Patients
Characteristic Mean 6 SE
Age (yr) 28.9 6 2.2
Weight (kg) 85.8 6 3.9
Height (cm) 179.4 6 1.4
Body mass index (kg/m2) 26.6 6 1.1
Heart rate (beats/min) 60.3 6 2.6
Systolic blood pressure (mm Hg) 120.7 6 2.2
Diastolic blood pressure (mm Hg) 70.6 6 1.5
Serum cholesterol (mg/dl) 181.9 6 10.5
Forearm volume (ml) 1,412 6 83
Table 2. Tissue-Type Plasminogen Activator Antigen at Baseline and After Infusion of Isoproterenol,
Methacholine and Sodium Nitroprusside in 15 Study Patients




(ml/100 ml per min)
1.4 6 0.2 9.7 6 1.9 8.7 6 1.9 6.7 6 1.1 , 0.001
Venous t-PA (ng/ml) 3.0 6 0.5 4.9 6 0.5 4.4 6 0.8 3.2 6 0.6 , 0.001
Arterial t-PA (ng/ml) 2.4 6 0.4 2.5 6 0.5 2.4 6 0.4 2.7 6 0.6 NS
AV gradient (ng/ml) 0.6 6 0.2 2.5 6 0.5 2.0 6 0.5 0.5 6 0.4 , 0.05
Net t-PA release
(ng/100 ml per min)
0.7 6 0.3 26.2 6 11.6 15.3 6 5.5 1.8 6 2.2 , 0.05
Data presented are mean value 6 SE. ANOVA 5 analysis of variance; AV 5 arteriovenous; BL 5 baseline; Iso 5
isoproterenol; Meth 5 methacholine; SNP 5 sodium nitroprusside; t-PA 5 tissue-type plasminogen activator.
Figure 1. Net release of t-PA antigen (mean 6 SE) across the forearm
at baseline (B) and after the intrabrachial artery infusion of isoproter-
enol (ISO) (400 ng/min), methacholine (METH) (8 mg/min) and SNP
(8 mg/min) (n 5 15). Statistical comparison of respective stimulated
values with baseline values is shown.
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arteriovenous difference and no net release across the forearm.
The infusion of isoproterenol, methacholine and SNP resulted
in no significant arteriovenous difference of PAI-1 antigen
(21.19 6 0.79, 20.65 6 0.98 and 20.09 6 1.1 ng/ml, respec-
tively, p 5 0.8 by ANOVA).
Clinically insignificant changes in heart rate or blood pres-
sure occurred only after the highest dose of isoproterenol (400
ng/min), which produced a minor increase in heart rate from
60.3 6 2.6 to 64.1 6 2.4 beats/min and systolic blood pressure
from 120.7 6 2.2 to 124.5 6 2.0 mm Hg and decreased diastolic
blood pressure from 70.6 6 1.5 to 65.7 6 1.6 mm Hg.
Discussion
Although vasoactive drugs and increased blood flow are
widely appreciated to influence systemic t-PA levels, the local
factors that regulate t-PA release are less well understood. In
the present study we found that local intrabrachial artery
infusion of isoproterenol and methacholine resulted in a rapid,
large and selective increase in t-PA release across the forearm.
These effects were independent of blood flow because SNP,
which increased forearm blood flow to a similar extent, had no
such effect. This conclusion is further supported by the obser-
vation that the proportional increases in t-PA release induced
by isoproterenol and methacholine were much greater than
their respective proportional increases in blood flow.
Isoproterenol-stimulated t-PA release. The findings of in-
creased t-PA antigen release in response to a beta-adrenergic
agonist extend the findings of previous studies demonstrating
increased plasma t-PA antigen concentrations after systemic
infusion of isoproterenol (14) and increased forearm t-PA
antigen release during mental stress (18), which induces sys-
temic adrenergic activation. Epinephrine, which is released in
response to stress, is the endogenous ligand for the beta-
adrenergic receptor but is a mixed adrenergic agonist with both
alpha- and beta-adrenergic effects. Previous studies (16) have
suggested that both alpha- and beta-adrenergic agonists in-
crease fibrinolysis. Thus, the specific role of the beta-
adrenergic receptor in the regulation of t-PA antigen release is
uncertain. In the present study, the beta-adrenergic receptor
agonist isoproterenol was found to increase acute t-PA secre-
tion in the forearm. This finding indicates that beta-adrenergic
receptors contribute to the regulation of t-PA antigen release
locally in the vasculature and may thus contribute to the
regulation of fibrinolysis under conditions associated with
increased adrenergic stimulation. Because there appear to be
regional variations in the production of t-PA in different
vascular beds (24) the proportional increase of t-PA in re-
sponse to b-adrenergic receptor stimulation in vascular beds
other than the forearm may differ.
The dose of isoproterenol infused intraarterially resulted in
systemic changes that were of minimal physiologic importance.
Heart rate increased by an average of 4 beats/min, and blood
pressure changed by ;5 mm Hg after the intraarterial infusion
of isoproterenol (400 ng/min). These minor autonomic
changes would not be expected to result in the large increase in
t-PA antigen across the forearm. That arterial t-PA antigen
concentrations did not increase after isoproterenol, whereas
venous concentrations did, confirms that systemic reflex re-
sponses did not contribute to the large increase in t-PA antigen
release across the forearm that occurred after infusion of
isoproterenol.
Methacholine-stimulated t-PA release. The findings of a
22-fold increase in t-PA antigen release after methacholine (8
mg/min) and no significant increase after SNP infusion are
consistent with the findings of Jern et al. (19), who reported a
12-fold increase in forearm t-PA release after the infusion of
methacholine (4 mg/min) and also found no net release of t-PA
antigen after the infusion of SNP. Methacholine, an
endothelium-dependent vasodilator, is thought to act on en-
dothelial muscarinic receptors, resulting in the activation of
NO synthase, with production of NO from L-arginine (25).
SNP, in contrast, is thought to release NO directly (25). We
used methacholine and SNP not only to localize the site of NO
responses but also to provide control data that would allow
comparison of the isoproterenol responses with those of other
agonists that increased forearm blood flow to a similar extent.
These comparisons are particularly important because shear
stress has been reported to increase t-PA release (26). How-
ever, because SNP had no effect on t-PA antigen release in the
present study, increased blood flow and consequent shear
stress do not explain the t-PA antigen responses to isoproter-
enol and methacholine. In addition, because methacholine
resulted in a marked release of t-PA antigen but SNP did not,
it is likely that the effects of NO on t-PA production are
endothelium dependent or that the effects of methacholine are
independent of NO, perhaps mediated directly through other
mechanisms such as effects on muscarinic receptors. However,
the observation that intraarterial administration of substance
P, which results in endothelium-dependent NO-mediated va-
sodilation, also increases t-PA release in the forearm (27)
suggests that an endothelium-dependent NO-mediated effect
is a possible explanation for the increase in t-PA release after
methacholine.
Endothelial fibrinolytic function. Active t-PA in plasma is
rapidly inhibited by PAI-1, with a second-order rate constant
of 107 mol/liter per s (28). Thus, the effect of a local increase
in t-PA release could potentially be offset by a simultaneous
increase in PAI-1 release. However, we found no evidence of
agonist-stimulated PAI-1 release in the forearm. Jern et al.
(18,19) also reported no net release of PAI-1 from the forearm
during mental stress or after the infusion of methacholine or
SNP.
Both constitutive and regulated secretion of t-PA has been
shown (29) to occur in human endothelial cells studied in vitro.
The rapidity with which t-PA increased in response to stimuli
such as thrombin in vitro suggests that release of stored t-PA,
rather than increased synthesis, accounts for much of the
increase. A similar mechanism is likely to explain the increase
in t-PA in response to isoproterenol and methacholine noted
in the present study. Local stimulated release of t-PA may play
an important role in fibrinolysis because the t-PA released by
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endothelial cells is enzymatically active, and high local concen-
trations are achieved (29). Recent studies (30) indicate that
t-PA is present in catecholamine storage vesicles and is
coreleased with catecholamines. Thus, a reservoir of t-PA in
catecholamine storage vesicles would be consistent with the
observations that stimuli that activate the adrenergic nervous
system, such as exercise and mental stress, also result in an
increase in t-PA concentrations. We previously showed (31)
that isoproterenol, acting through presynaptic beta-adrenergic
receptors, is a potent stimulus to the local release of norepi-
nephrine in the human forearm. Thus, we speculate that some
of the increase in t-PA release after isoproterenol represents
t-PA coreleased with norepinephrine from catecholamine stor-
age vesicles in the sympathetic nerve terminal.
The present study demonstrates a role for the beta-
adrenergic receptor in the regulation of local t-PA release, and
future studies will be required to define the relative importance of
beta1- and beta2-adrenoceptors. Also, because the increase in
forearm blood flow in response to both mental stress and
intraarterial isoproterenol may be partially mediated through
endothelial NO production (32), it will be of interest to define the
interrelation between the adrenergic nervous system and NO in
the regulation of fibrinolysis by the vascular endothelium.
Clinical implications. The major findings of the present
study demonstrating that local t-PA release is regulated rap-
idly, substantially and in a selective fashion by isoproterenol
and methacholine may be particularly pertinent to conditions
such as hypertension, heart failure and hypercholesterolemia
in which blunted endothelium-dependent NO responses, mea-
sured as NO-mediated vasodilation, occur (6–9). Furthermore,
in hypertension both endothelium-dependent NO-mediated va-
sodilation and beta-adrenergic receptor-mediated vasodilation
are blunted (6,7,33,34). Therefore in clinical settings that are
associated with impaired endothelium-mediated vasodilation, if a
deficient NO-mediated or a deficient adrenoceptor-mediated
t-PA release, or both, is also present, it may contribute to the
increased risk of myocardial infarction and stroke in these pa-
tients. Thus, studies comparing the regulation of vascular t-PA
release in healthy subjects and in patients with diseases such as
hypertension or hypercholesterolemia will be of interest.
Conclusions. Marked, rapid local t-PA release occurred in
response to isoproterenol, a beta-adrenoceptor agonist, and
methacholine, an endothelium-dependent NO agonist, in the
human forearm. This effect was selective and independent of
the effects of shear stress due to increased flow because SNP
induced similar increases in forearm blood flow without affect-
ing t-PA release. We speculate that vascular t-PA release may
be a potentially valuable tool for evaluating endothelial func-
tion in diseases associated with increased risk of thrombosis.
References
1. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in
plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3–9.
2. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasmino-
gen activator mass concentration on long-term mortality in patients with
coronary artery disease. Circulation 1993;88:2030–4.
3. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH.
Endogenous tissue-type plasminogen activator and risk of myocardial infarc-
tion. Lancet 1993;341:1165–8.
4. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic
activity, clotting factors, and long-term incidence of ischaemic heart disease
in the Northwick Park Heart Study. Lancet 1993;342:1076–9.
5. Margaglione M, Di Minno G, Grandone E, et al. Abnormally high levels of
tissue plasminogen activator and plasminogen activator inhibitor-1 in pa-
tients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol
1994;14:1741–5.
6. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-
dependent vascular relaxation in patients with essential hypertension. N Engl
J Med 1990;323:22–7.
7. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release
of endothelium-derived relaxing factor in human forearm circulation in vivo:
blunted response in essential hypertension. Circulation 1990;81:1762–7.
8. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-
dependent vasodilation is attenuated in patients with heart failure. Circula-
tion 1991;84:1589–96.
9. Creager MA, Cooke JP, Mendelson ME, et al. Impaired vasodilation of
forearm resistance vessels in hypercholesterolemic humans. J Clin Invest
1990;86:228–34.
10. Klocking HP. Release of plasminogen activator by acetylcholine from the
isolated perfused pig ear. Thromb Res 1979;16:261–4.
11. Emeis JJ. Perfused rat hindlegs. A model to study plasminogen activator
release. Thromb Res 1983;30:195–203.
12. Zhu GJ, Abbadini M, Donati MB, Mussoni L. Tissue-type plasminogen
activator release in response to epinephrine in perfused rat hindlegs. Am J
Physiol 1989;256:H404–10.
13. Chandler WL, Levy WC, Veith RC, Stratton JR. A kinetic model of the
circulatory regulation of tissue-type plasminogen activator during exercise,
epinephrine infusion, and endurance training. Blood 1993;81:3293–302.
14. Chandler WL, Levy WC, Stratton JR. The circulatory regulation of TPA
and UPA secretion, clearance, and inhibition during exercise and during
the infusion of isoproterenol and phenylephrine. Circulation 1995;92:
2984 –94.
15. Cash JD, Woodfield DG, Allan AGE. Adrenergic mechanisms in the
systemic plasminogen activator response to adrenaline in man. Br J Haema-
tol 1970;18:487–94.
16. Gader AMA, Clarkson AR, Cash JD. The plasminogen activator and
coagulation factor VII responses to adrenaline, noradrenaline, isoprenaline
and salbutamol in man. Thromb Res 1973;2:9–16.
17. de Boer A, Cluft C, Kroon JM, et al. Liver blood flow as a major determinant
of the clearance of recombinant human tissue-type plasminogen activator.
Thromb Haemost 1992;67:83–7.
18. Jern C, Selin L, Jern S. In vivo release of tissue-type plasminogen activator
across the human forearm during mental stress. Thromb Haemost 1994;72:
285–91.
19. Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen
activator in response to muscarinic receptor stimulation in human forearm.
Thromb Haemost 1994;72:588–94.
20. Lang CC, Stein CM, Brown RM, et al. Attenuation of isoproterenol-
mediated vasodilation in blacks. N Engl J Med 1995;333:155–60.
21. Stein CM, Lang CC, Nelson R, Brown M, Wood AJJ. Vasodilation in
African-Americans: attenuated nitric oxide-mediated responses. Clin Phar-
macol Ther 1997;62:436–43.
22. Whitney RJ. The measurement of volume changes in human limbs. J Physiol
1953;121:1–27.
23. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan
DE. Stimulation of plasminogen-activator inhibitor in vivo by infusion of
angiotensin II. Evidence of a potential interaction between the renin-
angiotensin system and fibrinolytic function. Circulation 1993;87:1969–73.
24. Keber D, Stegnar M, Kluft C. Different tissue plasminogen activator release
in the arm and leg during venous occlusion is equalized after DDAVP
infusion. Throm Haemost 1990;63:72–5.
25. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiol-
ogy and pharmacology. Pharmacol Rev 1991;43:109–42.
26. Diamond SL, Eskin SG, McIntire LV. Fluid flow stimulates tissue plasmin-
ogen activator secretion by cultured human endothelial cells. Science
1989;243:1483–5.
27. Newby DE, Wright RA, Ludlam CA, Fox KAA, Webb DJ. An in vivo model
121JACC Vol. 32, No. 1 STEIN ET AL.
July 1998:117–22 LOCAL VASCULAR t-PA REGULATION
for the assessment of acute fibrinolytic capacity of the endothelium. Throm
Haemost 1997;78:1242–8.
28. Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a
fast-acting inhibitor of plasminogen activators in human plasma. Blood
1984;64:907–13.
29. van den Eijnden-Schrauwen Y, Kooistra T, de Vries REM, Emeis JJ. Studies
on the acute release of tissue-type plasminogen activator from human
endothelial cells in vitro and in rats in vivo: evidence of a dynamic storage
pool. Blood 1995;85:3510–7.
30. Parmer RJ, Mahata M, Mahata S, Sebald MT, O’Connor DT, Miles LA.
Tissue plasminogen activator (t-PA) is targeted to the regulated secretory
pathway. J Biol Chem 1997;272:1976–82.
31. Stein M, Deegan R, He H, Wood AJJ. Beta-adrenergic receptor mediated
release of norepinephrine in the human forearm. Clin Pharmacol Ther
1993;54:58–64.
32. Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhibition of the L-arginine/
nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in
human forearm. Circulation 1997;95:2293–7.
33. Naslund T, Silbertstein DJ, Merrell WJ, Nadeau JH, Wood AJJ. Low sodium
intake corrects abnormality in beta-receptor mediated arterial vasodilation
in patients with hypertension: correlation with beta-receptor function in
vitro. Clin Pharmacol Ther 1990;48:87–95.
34. Stein CM, Nelson R, Deegan R, He H, Wood M, Wood AJJ. Forearm beta
adrenergic receptor-mediated vasodilation is impaired, without alteration of
forearm norepinephrine spillover, in borderline hypertension. J Clin Invest
1995;96:579–85.
122 STEIN ET AL. JACC Vol. 32, No. 1
LOCAL VASCULAR t-PA REGULATION July 1998:117–22
